You guys are crazy to think TEVA has any obligation to ATRS.
One of the adverse effects of testosterone replacements is the potential for raising the hematocrit which means that you have more blood cells & this can increase the risk for blood clots. No idea why they claim an injector would effect the hematocrit.
The May calls seem like a smart play.
I'm skeptical of both so that's how I group them together. The only reason I'm taking a flyer with CLDN is because the Phase 1 data was promising but I still don't trust it.
I can tell you that FLML is controlling the market. My hospital only buys the cheapest drugs available & we're 100% FLML for Blox & Vazculep. My pharmacy is ticked off at the increased pricing but they have no option.
I use Vazculep 1ml vials on occasion to mix an infusion but most of the time I use pre-filled syringes that are supplied by a compounding pharmacy. The pharmacy can take one 10ml vial & produce 100 syringes. It makes sense for FLML to increase the pricing since the pre-filled syringes are becoming common practice.
Only for the brave or stupid.
"Adam Feuerstein on ATHX - "Handicapping the outcome of the stroke study is a shot in the dark. Athersys has no prior clinical data using MultiStem in stroke patients. The company based the phase II study on preclinical experiments demonstrating neurological and functional improvement in mice with strokes treated with MultiStem"
I did the same thing with CLDN so I can't fault you . Huge win on positive data but probably a stupid bet.
What about all the posters who guaranteed Medac would lose the patent challenge.?
yes, I always thought Medac had a 50% chance of stopping ATRS from marketing some dosages.
Congrats on ADRO. I wasn't going to buy a 90% gainer at the open of trading but the biotech bubble continues on. Ridiculous,
I didn't think it was strange when I saw the headline. They received a 18-3 negative vote on the safety & 18-2 negative advisory vote in Sept. They need to run another Phase III trial & potentially would be several years behind LPCN in going to market with an inferior drug. In addition, the market is wary of testosterone replacements.
Now that they lowered their price target why would you follow their advice?